Blanca Velasco

Dr. Blanca Velasco

University Hospital Salamanca

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ICIgnacio Cruz-González
Ignacio Cruz-González
KKKasper Korsholm
Kasper Korsholm
Blanca VelascoBlanca Velasco
Blanca Velasco
JTJean Benoit Thambo
Jean Benoit Thambo
PMPatrizio Mazzone
Patrizio Mazzone
JNJens Erik Nielsen-Kudsk
Jens Erik Nielsen-Kudsk

Verified
Journal Article
Open access
PDF file
Blanca VelascoBlanca Velasco
Blanca Velasco
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
FCFernando Carrasco-Chinchilla
Fernando Carrasco-Chinchilla
FFFelipe Fernández-Vázquez
Felipe Fernández-Vázquez
DADabit Arzamendi
Dabit Arzamendi
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). Methods: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. Results: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. Conclusions: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.

1 April 2016 in Revista Clínica Española
Verified
Journal Article
Closed access
Blanca VelascoBlanca Velasco
Blanca Velasco
OFOscar Fabregat-Andrés
Oscar Fabregat-Andrés
VMV. Montagud
V. Montagud
SMS. Morell
S. Morell
JNJulio Núñez
Julio Núñez
LFL. Fácila
L. Fácila

25 March 2021 in Polish Heart Journal
Verified
Journal Article
Closed access
ICIgnacio Cruz-González
Ignacio Cruz-González
Blanca VelascoBlanca Velasco
Blanca Velasco
Oral anticoagulation (OAC) is the standard of care for stroke prevention in atrial fibrillation, but it is associated with a substantial risk of bleeding complications and its effect depends on optimal patient's compliance. In patients with nonvalvular atrial fibrillation, the left atrial appendage is the source of thrombi that may cause stroke in up to 91% to 95% of cases. Thus, percutaneous left atrial appendage occlusion (LAAO) is being increasingly performed as an alternative to OAC for stroke prophylaxis in patients at increased bleeding risk. The current evidence supporting LAAO derives from 3 randomized controlled trials: 2 on Watchman device use in patients eligible for short-term OAC and a more recent trial comparing LAAO with Amulet and Watchman device use versus long-term OAC with direct oral anticoagulants (DOACs). In addition, numerous real-life registries have reported favorable outcomes with Watchman, ACP, and Amulet devices in patients at higher bleeding risk and / or formal contraindications to short-term OAC, employing less intensive antithrombotic regimens after LAAO. Furthermore, there has been growing evidence on newer devices with distinct features that might be of value to specific subgroups of patients. However, several issues remain unresolved including optimal patient and device selection, individual tailoring of postprocedural antithrombotic therapy, and management of periprocedural complications such as device-related thrombus and residual peridevice leaks. Finally, the relative benefit of LAAO versus DOACs should be further assessed across the spectrum of patient candidacy for DOACs, over extended follow-up periods. In this article, we review the body of evidence supporting LAAO with currently available devices.

18 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
PMPablo Luengo Mondéjar
Pablo Luengo Mondéjar
Blanca VelascoBlanca Velasco
Blanca Velasco
JGJean Carlos Núñez García
Jean Carlos Núñez García
RGRocío González-Ferreiro
Rocío González-Ferreiro
PSPedro L. Sánchez
Pedro L. Sánchez
Background: Paravalvular leak occurs in 5–17% of patients following surgical valve replacement, more often in mitral position. The prognosis without treatment is poor. Percutaneous device closure represents an alternative to repeat surgery. The objective of this work is to evaluate the medium and long-term results in the percutaneous closure of PVL in mitral prosthesis. Methods: This observational study is based on a retrospective registry including consecutive mitral PVL cases undergoing percutaneous closure at a single tertiary-care center from April 2010 to December 2020. The safety and efficacy results of the procedure, at 90 days and in the long term, were analyzed. Also, predictors of procedure failure and long-term events were identified. Results: A total of 128 consecutive mitral paravalvular leak closure procedures were included. Technical success was achieved in 115 (89.8%) procedures. The presence of multiple PVLs was the sole factor that independently predicted procedural failure. Median follow-up of our sample was 41.8 months (mean 47.7 ± 35.7 months). Underlying hemolytic anemia as the indication for PVL closure, a recent admission for decompensated HF, and lack of improvement in functional class emerged as consistent predictors of MACE and death during long-term follow-up, while lack of procedural success during the first PVL procedure and chronic kidney disease were also associated with MACE during follow-up. Conclusions: Percutaneous mitral PVL closure displayed high technical and procedural success rates, with an acceptable safety profile, in a high-risk population. Percutaneous mitral PVL closure achieved an improvement in short- and long-term functional class and a reduction of hemolysis in the vast majority of patients. In addition, long-term survival in our study was good, in particular for patients undergoing successful PVL closure procedures.

1 March 2017 in Medicina Intensiva (English Edition)
Verified
Journal Article
Closed access
RER. de la Espriella-Juan
R. de la Espriella-Juan
AVA. Valls-Serral
A. Valls-Serral
Blanca VelascoBlanca Velasco
Blanca Velasco
ABA. Berenguer-Jofresa
A. Berenguer-Jofresa
ÓFÓ. Fabregat-Andrés
Ó. Fabregat-Andrés
SMS. Morell-Cabedo
S. Morell-Cabedo